Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0338)
| Name |
Typhaneoside
|
||||
|---|---|---|---|---|---|
| Synonyms |
Typhaneoside; 104472-68-6; CHEMBL450526; CHEBI:191968; HY-N0712; s9076; AKOS037514873; CCG-270457; CS-0009730; 3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C34H42O20
|
||||
| IUPAC Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
|
||||
| Canonical SMILES |
CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)OC6C(C(C(C(O6)C)O)O)O)O)O)O)O)O
|
||||
| InChI |
InChI=1S/C34H42O20/c1-10-20(38)24(42)27(45)32(49-10)48-9-18-22(40)26(44)31(54-33-28(46)25(43)21(39)11(2)50-33)34(52-18)53-30-23(41)19-15(37)7-13(35)8-17(19)51-29(30)12-4-5-14(36)16(6-12)47-3/h4-8,10-11,18,20-22,24-28,31-40,42-46H,9H2,1-3H3/t10-,11-,18+,20-,21-,22+,24+,25+,26-,27+,28+,31+,32+,33-,34-/m0/s1
|
||||
| InChIKey |
POMAQDQEVHXLGT-QDYYQVSOSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Responsed Disease | Acute myeloid leukaemia | ICD-11: 2A60 | |||
| Responsed Regulator | 5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) | Driver | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Apoptosis | hsa04210 | ||||
| Autophagy | hsa04140 | ||||
| AMPK signaling pathway | hsa04152 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| Cell apoptosis | |||||
| Cell autophagy | |||||
| In Vitro Model | KAS-6/1 cells | Plasma cell myeloma | Homo sapiens | CVCL_9544 | |
| HL-60 cells | Adult acute myeloid leukemia | Homo sapiens | CVCL_0002 | ||
| NB4 cells | Acute promyelocytic leukemia | Homo sapiens | CVCL_0005 | ||
| K-562 cells | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | ||
| HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
| In Vivo Model |
4-week-old BALB/c malenude mice(Peking University Health Science Center, Beijing, China) were subcutaneously injection with HL60 cells (1 x 107). After tumor volume reached 50 mm3, mice were randomly divided into 4 groups (n = 16/group). TYP was administered intraperitoneal injection once a day at 10, 20 and 30 mg/kg body weight and the mice in normal control group were received equal amounts of 10% DMSO in sterile corn oil.
Click to Show/Hide
|
||||
| Response regulation | Typhaneoside (TYP) significantly triggered autophagy in acute myeloid leukemia (AML) cells by promoting the activation of AMP-activated protein kinase (AMPK) signaling, contributing to ferritin degradation, ROS accumulation and ferroptotic cell death ultimately. | ||||